Starpharma receives TGA approval for VivaGel

Company News

by Jessica Amir

A developer of dendrimer products, Starpharma (ASX:SPL) has received Australian marketing approval from the Therapeutic Goods of Administration (TGA) for its product, VivaGel, that treats bacterial vaginosis.

Starpharma’s VivaGel is now expected to be available in pharmacies in the new year.

The product developed by Starpharma, will be marketed by Aspen Pharmacare as Fleurstat BV gel, carrying the VivaGel brand.

Aspen will also promote and distribute the product to clinicians and pharmacies in Australia and New Zealand.

Shares in Starpharma (ASX:SPL) are trading 3.36 per cent higher to $1.39.


Jessica Amir

Finance News Network
Jessica is a senior finance journalist and presents the Market Outlook, Market at Midday and Market Wrap. She also presents ASX company news and interviews CEOs. She joined FNN in January 2017 with six years of broadcast journalism experience. She worked as a journalist and producer with Sky News Business, ABC 1, ABC's The Business and ABC24. She also worked in regional Australia for Prime 7 and WIN News as a TV reporter. In her prior life she worked as a financial planner.